A new RNA vaccine platform based on MS2 virus-like particles produced in Saccharomyces cerevisiae

Biochemical and Biophysical Research Communications

Volumn 407, Issue 1, 2011, Pages 124-128

  Sun, Shipeng ^a,b   Li, Wenli ^a,b   Sun, Yu ^a,b   Pan, Yang ^a,b   Li, Jinming ^b  

^a GRADUATE SCHOOL OF PEKING UNION MEDICAL COLLEGE   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

HIV 1 gag; MRNA packaging; MS2 virus like particles; RNA vaccine

Indexed keywords

GAG PROTEIN; MESSENGER RNA; RNA VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; FEMALE; GENETIC IMMUNIZATION; HELA CELL; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VIVO STUDY; MOUSE; MS2 VIRUS; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; VIRUS LIKE AGENT;

ANIMALS; ANTIGEN-ANTIBODY REACTIONS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; LEVIVIRUS; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; RNA, MESSENGER; RNA, VIRAL; SACCHAROMYCES CEREVISIAE; VIRAL VACCINES; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; SACCHAROMYCES CEREVISIAE;

EID: 79953164843     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.02.122     Document Type: Article

References (33)

1. Vogel F.R., Sarver N. Nucleic acid vaccines. Clin. Microbiol. Rev. 1995, 8:406-410.
2. Tang D.C., DeVit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 1992, 356:152-154.
3. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., Hawe L.A., Leander K.R., Martinez D., Perry H.C., Shiver J.W., Montgomery D.L., Liu M.A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745-1749.
4. Wang Z., Troilo P.J., Wang X., Griffiths T.G., Pacchione S.J., Barnum A.B., Harper L.B., Pauley C.J., Niu Z., Denisova L., Follmer T.T., Rizzuto G., Ciliberto G., Fattori E., Monica N.L., Manam S., Ledwith B.J. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. 2004, 11:711-721.
5. Manam S., Ledwith B.J., Barnum A.B., Troilo P.J., Pauley C.J., Harper L.B., Griffiths T.G., Niu Z., Denisova L., Follmer T.T., Pacchione S.J., Wang Z., Beare C.M., Bagdon W.J., Nichols W.W. Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 2000, 43:273-281.
6. Martin T., Parker S.E., Hedstrom R., Le T., Hoffman S.L., Norman J., Hobart P., Lew D. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum. Gene Ther. 1999, 10:759-768.
7. Conry R.M., LoBuglio A.F., Wright M., Sumerel L., Pike M.J., Johanning F., Benjamin R., Lu D., Curiel D.T. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 1995, 55:1397-1400.
8. Probst J., Weide B., Scheel B., Pichler B.J., Hoerr I., Rammensee H.G., Pascolo S. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther. 2007, 14:1175-1180.
9. Bringmann A., Held S.A., Heine A., Brossart P. RNA vaccines in cancer treatment. J. Biomed. Biotechnol. 2010, 2010:623687.
10. Fleeton M.N., Chen M., Berglund P., Rhodes G., Parker S.E., Murphy M., Atkins G.J., Liljestrom P. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J. Infect. Dis. 2001, 183:1395-1398.
11. Weiss R., Scheiblhofer S., Roesler E., Ferreira F., Thalhamer J. Prophylactic mRNA vaccination against allergy. Curr. Opin. Allergy Clin. Immunol. 2010, 10:567-574.
12. Roesler E., Weiss R., Weinberger E.E., Fruehwirth A., Stoecklinger A., Mostbock S., Ferreira F., Thalhamer J., Scheiblhofer S. Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. J. Allergy Clin. Immunol. 2009, 124:1070-1077.
13. Kyte J.A., Kvalheim G., Aamdal S., Saeboe-Larssen S., Gaudernack G. Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. Cancer Gene Ther. 2005, 12:579-591.
14. Cheng W.F., Hung C.H., Chai C.Y., Hsu K.F., He L., Ling M., Wu T.C. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J. Virol. 2001, 75:2368-2376.
15. Ghaemi A., Soleimanjahi H., Gill P., Hassan Z., Jahromi S.R., Roohvand F. Recombinant lambda-phage nanobioparticles for tumor therapy in mice models. Genet. Vaccines Ther. 2010, 8:3.
16. Lankes H.A., Zanghi C.N., Santos K., Capella C., Duke C.M., Dewhurst S. In vivo gene delivery and expression by bacteriophage lambda vectors. J. Appl. Microbiol. 2007, 102:1337-1349.
17. Legendre D., Fastrez J. Production in Saccharomyces cerevisiae of MS2 virus-like particles packaging functional heterologous mRNAs. J. Biotechnol. 2005, 117:183-194.
18. Cellini S., Fortini C., Gallerani E., Destro F., Cofano E.B., Caputo A., Gavioli R. Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice. Virol. J. 2008, 5:81.
19. Horn W.T., Convery M.A., Stonehouse N.J., Adams C.J., Liljas L., Phillips S.E., Stockley P.G. The crystal structure of a high affinity RNA stem-loop complexed with the bacteriophage MS2 capsid: further challenges in the modeling of ligand-RNA interactions. RNA 2004, 10:1776-1782.
20. Lowary P.T., Uhlenbeck O.C. An RNA mutation that increases the affinity of an RNA-protein interaction. Nucleic Acids Res. 1987, 15:10483-10493.
21. Gietz R.D., Woods R.A. Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method. Methods Enzymol. 2002, 350:87-96.
22. Zhan S., Li J., Xu R., Wang L., Zhang K., Zhang R. Armored long RNA controls or standards for branched DNA assay for detection of human immunodeficiency virus type 1. J. Clin. Microbiol. 2009, 47:2571-2576.
23. Wei Y., Yang C., Wei B., Huang J., Wang L., Meng S., Zhang R., Li J. RNase-resistant virus-like particles containing long chimeric RNA sequences produced by two-plasmid coexpression system. J. Clin. Microbiol. 2008, 46:1734-1740.
24. Pasloske B.L., Walkerpeach C.R., Obermoeller R.D., Winkler M., DuBois D.B. Armored RNA technology for production of ribonuclease-resistant viral RNA controls and standards. J. Clin. Microbiol. 1998, 36:3590-3594.
25. March J.B., Jepson C.D., Clark J.R., Totsika M., Calcutt M.J. Phage library screening for the rapid identification and in vivo testing of candidate genes for a DNA vaccine against Mycoplasma mycoides subsp. mycoides small colony biotype. Infect. Immun. 2006, 74:167-174.
26. Clark J.R., March J.B. Bacteriophage-mediated nucleic acid immunisation. FEMS Immunol. Med. Microbiol. 2004, 40:21-26.
27. Brown W.L., Mastico R.A., Wu M., Heal K.G., Adams C.J., Murray J.B., Simpson J.C., Lord J.M., Taylor-Robinson A.W., Stockley P.G. RNA bacteriophage capsid-mediated drug delivery and epitope presentation. Intervirology 2002, 45:371-380.
28. Wu M., Brown W.L., Stockley P.G. Cell-specific delivery of bacteriophage-encapsulated ricin A chain. Bioconjug. Chem. 1995, 6:587-595.
29. Wu M., Sherwin T., Brown W.L., Stockley P.G. Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids. Nanomedicine 2005, 1:67-76.
30. Wei B., Wei Y., Zhang K., Wang J., Xu R., Zhan S., Lin G., Wang W., Liu M., Wang L., Zhang R., Li J. Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide. Biomed. Pharmacother. 2009, 63:313-318.
31. Su Z., Dannull J., Yang B.K., Dahm P., Coleman D., Yancey D., Sichi S., Niedzwiecki D., Boczkowski D., Gilboa E., Vieweg J. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J. Immunol. 2005, 174:3798-3807.
32. Y. Yuki, T. Nochi, H. Kiyono, Progress towards an AIDS mucosal vaccine: an overview, Tuberculosis (Edinb.) 87 (Suppl. 1) (2007) S35-S44.
33. C. Domingo, I. Gadea, M. Pardeiro, C. Castilla, S. Fernandez, M.A. Fernandez-Clua, J.J. De la Cruz Troca, C. Punzon, F. Soriano, M. Fresno, E. Tabares, Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D, Vaccine 21 (2003) 3565-3574.